All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2018-07-04T09:36:08.000Z

EHA 2018 | Outcomes of the phase II study of tazemetostat in patients with R/R FL

Jul 4, 2018
Share:

Bookmark this article

On Friday 15th June an oral abstract session took place at the 23rd congress of the European Hematology Association (EHA). Abstract S100 was presented by Gilles Salles, South Lyon University Hospital Complex, Lyon, on the interim update of the phase II study of tazemetostat in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

Tazemetostat is a selective, reversible, oral inhibitor of mutated and wild-type EZH2. It has shown activity and acceptable safety profiles as monotherapy in phase I and II studies in R/R non-Hodgkin lymphoma (NHL).

Study Overview

  • Multi-center, open-label study in 6 cohorts of patients who have had ≥2 lines of therapy
  • The primary endpoint was objective response rate (ORR) and secondary endpoints were progression-free survival (PFS), duration of response (DOR), safety and tolerability
  • The outcomes of this study were focused on patients with R/R FL
  • Patients received 800mg of tazemetostat twice daily until disease progression or withdrawal

Key Findings

  • Patients evaluable for efficacy = FL wild-type (WT) EZH2 (n=54) and FL mutated (MT) EZH2 (n=28)
    • The ORR for FL EZH2 MT = 71% (n=20) vs FL EZH2 WT = 33% (n=18)
    • The overall ORR was 46%
  • Out of the 28 patients with FL EZH2 MT, 100% had evidence of tumor reduction vs 77.5% of patients with FL EZH2 WT
  • Patients evaluable for safety (n=82)
    • The most frequent treatment-emergent adverse events (AEs) grade ≥3 were thrombocytopenia (6%), anemia (6%), asthenia (4%) and fatigue (2%)
    • The most frequent treatment-related AEs grade ≥3 were thrombocytopenia (4%), anemia (4%), asthenia (1%) and fatigue (1%)

Dr Salles concluded his talk by stating that the interim data of this study demonstrated clinical activity of tazemetostat in R/R FL patients with previous lines of therapy. It showed durable clinical responses and also that tazemetostat was well tolerated. These promising findings support EZH2 as a potential novel therapeutic target in R/R FL.

  1. Salles G. Interim update from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory (R/R) follicular lymphoma (FL). Abstract S100. 23rd Congress of EHA, Stockholm, Sweden

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
46 votes - 76 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox